Treating ovarian cancer cell lines SKOV3, OVCAR5 and IGROV1 with a PI3K inhibitor, LY294002, there is a reduction in gondatropin-induced MMP-2 activity with little change in MMP-9 activity [42]. This evidence concerns the gene MMP9 and ovarian carcinoma.